As on 31 March, 2018, Jubilant had a total of 94 ANDAs for oral solids filed in the US, the company said. New Delhi:Jubilant Life Sciences Ltd on Tuesday said it has received the final approval from USFDA for its generic Niacin extended-release tablets used for controlling cholesterol levels. The approval granted by the US Food and Drug Administration (USFDA) to the company’s wholly-owned arm Jubilant Pharma Ltd, is for multiple strengths of Niacin extended-release tablets of 500 mg, 750 mg, and 1,000 mg, the company said in a statement. “This is the first approval that we have received from the USFDA during the current financial year,” it said. As on 31 March, 2018, Jubilant had a total of 94 ANDAs for oral solids filed in the US, the company said.

Source: Mint May 15, 2018 10:52 UTC